January 1, 2011Clinical Chemistry and Laboratory Medicine (CCLM)
Role of biomarkers in cardioncology
Population
Cancer patients receiving anticancer drugs at risk of cardiotoxicity
Comparison
Cardiac biomarkers for early detection of… vs Current standard for monitoring cardiac function
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support troponin I monitoring in cancer patients; hypothesis-generating and requires randomized confirmation before practice change.
Structured PICO
P
Population
Cancer patients receiving anticancer drugs at risk of cardiotoxicity
I
Intervention
Cardiac biomarkers (specifically troponin I) for early detection of subclinical cardiac injury and angiotensin-converting enzyme inhibitors for prevention
C
Comparator
Current standard for monitoring cardiac function (detecting functional impairment after it has occurred)
O
Outcome
Early detection of subclinical cardiac injury, prevention of left ventricular ejection fraction reduction, and prevention of late cardiac events
Cardiac biomarkers, particularly troponin I, provide an effective strategy for the early detection of subclinical cardiotoxicity in cancer patients, enabling preventive therapy with ACE inhibitors.
Cite This Study
Cardinale et al. (2011) studied this question.